Bioequivalence and Bio availability

Bioavailability can be referred to as the rate and extent to which active ingredient or active element of the drug product is absorbed and becomes available at the site of action. The extent and rate of drug absorption are usually measured by the area under the blood or plasma concentration-time curve  (AUC) and the maximum concentration (C max), respectively. 

Bioequivalence: When two drug products or two formulations of the same drug provide the same therapeutic effect, they are said to be bioequivalent, or, that they are therapeutically equivalent. It means, their rates and extent of absorptions do not reflect a significant difference at the site of action.


    Related Conference of Bioequivalence and Bio availability

    April 24-25, 2024

    33rd Neonatology and Primary Care Congress

    Paris, France
    April 30-30, 2024

    14th International Conference on Womens Health and Cancer Cure

    Amsterdam, Netherlands
    July 25-26, 2024

    20th World Summit on Blockchain Technology

    Amsterdam, Netherlands
    August 20-21, 2024

    11th World Summit on Epilepsy and Bipolar Disorders

    Montreal, Canada
    September 26-27, 2024

    7th Annual Congress on Emergency Medicine and Acute Care

    Amsterdam, Netherlands
    October 14-15, 2024

    11th World Machine Learning and Deep learning Conference

    Barcelona, Spain

    Bioequivalence and Bio availability Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in